/Rollins%2C%20Inc_%20workspace%20by-%20MacroEcon%20via%20Shutterstock.jpg)
With a market cap of $27.5 billion, Rollins, Inc. (ROL) is a global leader in pest and termite control services, best known for its flagship brand Orkin. Headquartered in Atlanta, Georgia, the company operates in over 70 countries, serving residential and commercial clients.
Companies valued at $10 billion or more are generally described as “large-cap stocks,” and Rollins definitely fits that description. With a highly recurring revenue model, Rollins delivers consistent growth through a mix of organic expansion and strategic acquisitions. Its business is considered recession-resistant, supported by strong cash flow, low debt, and over two decades of dividend increases.
ROL recently touched its 52-week high of 58.65 on June 3 and is currently trading 3.8% below the peak. Shares of Rollins have gained over 8.9% over the past three months, surpassing the broader Dow Jones Industrial Average’s ($DOWI) marginal rise during the same time frame.
Rollins has gained an impressive 21.7% year-to-date, significantly outperforming the Dow Industrials’ marginal decline. Over the past 52 weeks, ROL shares have climbed 14.5%, also beating the Dow’s 8.9% gain during the same period.
The stock has been trading above the 50-day and 200-day moving averages since the end of January, indicating an uptrend.
Rollins’ stock edged marginally following its Q1 2025 earnings release on April 23. The company reported $822.5 million in revenue, reflecting a 9.9% year-over-year increase and topping the $816.2 million consensus. Adjusted operating income rose 6.7% to $147 million, with margins holding steady at 17.9%. Adjusted EPS came in at $0.22, up 10% year-over-year, matching analyst forecasts.
In the competitive pest control and services space, contender H&R Block, Inc. (HRB) has trailed behind Rollins in terms of performance. HRB shares are up 6.4% over the past 52 weeks and have posted a modest 4.8% gain year-to-date, falling short of ROL’s stronger returns over both periods.
Among the 10 analysts covering the stock, there is a consensus rating of “Moderate Buy,” and the mean price target of $57.11 reflects a premium of 1.2% from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
